Wittes, Janet

Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial

Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet

Retinal Development and DisordersVirus-based gene therapy research

Cited by 1,952

Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 890

Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy

Maguire, A. M., Russell, S., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., et al. (2019) · Ophthalmology

Retinal Development and DisordersVirus-based gene therapy research

Cited by 409

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Wanner, C., Green, J. B., Hauske, S. J., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., et al. (2022) · Nephrology Dialysis Transplantation

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 110

Beware of on-treatment safety analyses

Yang, F., Wittes, J., & Pitt, B. (2019) · Clinical Trials

Statistical Methods in Clinical TrialsAdvanced Causal Inference Techniques

Cited by 29